6 completed. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 1 | Completed 1 |
Follow Cutaneous Squamous Cell Carcinoma: new trials by email Literature Review of Cutaneous Squamous Cell Carcinoma trials Research Report on Cutaneous Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IFx-Hu2.0 for the Treatment of Patients With Skin Cancer IFx-Hu2.0 - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Completed | TuHURA Biosciences, Inc. | 5 | 2021-06-10 | 2024-08-02 |
| Cemiplimab in AlloSCT/SOT Recipients With CSCC Cemiplimab, Everolimus, Sirolimus - Cutaneous Squamous Cell Carcinoma, Advanced Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 12 | 2020-11-03 | 2025-04-23 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors INCB099280 - Advanced Solid Tumor, MSI-H/dMMR Tumors | Phase 1 | Completed | Incyte Corporation | 182 | 2020-09-04 | 2025-07-14 |
| Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers IFx-Hu2.0 - Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Phase 1 | Completed | TuHURA Biosciences, Inc. | 23 | 2020-03-03 | 2024-09-23 |
| Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma Cemiplimab - Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | Completed | Regeneron Pharmaceuticals | 97 | 2019-04-11 | 2026-01-21 |
| Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Lenvatinib Pill, Cetuximab - Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 24 | 2018-04-30 | 2025-05-13 |
Carcinoma, Basal Cell (2) · Carcinoma, Merkel Cell (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Mesothelioma (1) · Nasopharyngeal Carcinoma (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uterine Cervical Neoplasms (1)
Carcinoma (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms (4) · Adenocarcinoma (2) · Carcinoma, Neuroendocrine (2) · Carcinoma, Squamous Cell (2) · DNA Virus Infections (2) · Infections (2) · Neoplasms by Site (2) · Neoplasms, Basal Cell (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2)
cemiplimab (2) · Cetuximab (1) · Everolimus (1) · Prednisone (1) · Sirolimus (1) · lenvatinib (1)
TuHURA Biosciences, Inc. (2) · Dana-Farber Cancer Institute (1) · Incyte Corporation (1) · Memorial Sloan Kettering Cancer Center (1) · Regeneron Pharmaceuticals (1)
United States (6) · Australia (2) · Belgium (1) · France (1) · Japan (1) · Netherlands (1)
Andrew S Brohl, MD (1) · Glenn J Hanna, MD (1) · Lara Dunn, MD (1)
PMID 33477979, PMID 36821617, PMID 38252908, PMID 42580817
2019 (1)